228 related articles for article (PubMed ID: 22569203)
1. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.
Claw KG; Beans JA; Lee SB; Avey JP; Stapleton PA; Scherer SE; El-Boraie A; Tyndale RF; Nickerson DA; Dillard DA; Thummel KE; Robinson RF
Nicotine Tob Res; 2020 May; 22(6):910-918. PubMed ID: 31241144
[TBL] [Abstract][Full Text] [Related]
3. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
4. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
5. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.
Swan GE; Lessov-Schlaggar CN; Bergen AW; He Y; Tyndale RF; Benowitz NL
Pharmacogenet Genomics; 2009 May; 19(5):388-98. PubMed ID: 19300303
[TBL] [Abstract][Full Text] [Related]
6. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
7. Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke.
Schaefer KR; Avey JP; Todd MR; Beans JA; Dillard DA; Shireman LM; Thornton TA; Tyndale RF; Thummel KE; Robinson RF; Claw KG
Clin Transl Sci; 2021 Nov; 14(6):2474-2486. PubMed ID: 34520119
[TBL] [Abstract][Full Text] [Related]
8. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
9. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Ho MK; Mwenifumbo JC; Al Koudsi N; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2009 Jun; 85(6):635-43. PubMed ID: 19279561
[TBL] [Abstract][Full Text] [Related]
10. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
11. Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.
Nagano T; Shimizu M; Kiyotani K; Kamataki T; Takano R; Murayama N; Shono F; Yamazaki H
Int J Environ Res Public Health; 2010 Jul; 7(7):2953-64. PubMed ID: 20717551
[TBL] [Abstract][Full Text] [Related]
12. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Mwenifumbo JC; Al Koudsi N; Ho MK; Zhou Q; Hoffmann EB; Sellers EM; Tyndale RF
Hum Mutat; 2008 May; 29(5):679-88. PubMed ID: 18360915
[TBL] [Abstract][Full Text] [Related]
13. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
Trials; 2011 Jan; 12():22. PubMed ID: 21266057
[TBL] [Abstract][Full Text] [Related]
14. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
Zhang X; Ameno K; Ameno S; Kinoshita H; Kubota T; Kumihashi M; Mostofa J; Iwahashi K; Ijiri I
Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
[TBL] [Abstract][Full Text] [Related]
15. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
16. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.
Lea RA; Dickson S; Benowitz NL
J Anal Toxicol; 2006; 30(6):386-9. PubMed ID: 16872570
[TBL] [Abstract][Full Text] [Related]
17. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.
Zhu AZ; Renner CC; Hatsukami DK; Swan GE; Lerman C; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):708-18. PubMed ID: 23371292
[TBL] [Abstract][Full Text] [Related]
18. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users.
Zhu AZ; Renner CC; Hatsukami DK; Benowitz NL; Tyndale RF
Addiction; 2013 Oct; 108(10):1818-28. PubMed ID: 23692359
[TBL] [Abstract][Full Text] [Related]
19. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys.
Ferguson CS; Miksys S; Palmour RM; Tyndale RF
J Pharmacol Exp Ther; 2012 Dec; 343(3):628-37. PubMed ID: 22935730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
